Clopidogrel sulfate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317556

CAS#: 120202-66-6 (sulfate)

Description: Clopidogrel (INN) is an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, cerebrovascular disease, and to prevent myocardial infarction (heart attack) and stroke. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Clopidogrel acts by inhibiting the ADP receptor on platelet cell membranes. It is a prodrug, which requires CYP2C19 for its activation.

Chemical Structure

img
Clopidogrel sulfate
CAS# 120202-66-6 (sulfate)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317556
Name: Clopidogrel sulfate
CAS#: 120202-66-6 (sulfate)
Chemical Formula: C16H18ClNO6S2
Exact Mass: 0.00
Molecular Weight: 419.891
Elemental Analysis: C, 45.77; H, 4.32; Cl, 8.44; N, 3.34; O, 22.86; S, 15.27

Price and Availability

Size Price Availability Quantity
1g USD 90 Ready to ship
5g USD 250 Ready to ship
10g USD 365 Ready to ship
25g USD 750 Ready to ship
Bulk inquiry

Related CAS #: 120202-66-6 (bisulfate)   120202-65-5 (HCl)   90055-48-4 (racemic)   744256-69-7 (besylate)   120202-67-7 (HBr)    

Synonym: Plavix; (S)-Clopidogrel; Clopidogrelum; Zyllt. Clopidogrel sulfate; Osvix; Plavitor, SR 25990C; SR-25990C; SR25990C; SR 25990.

IUPAC/Chemical Name: methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate sulfate

InChi Key: FDEODCTUSIWGLK-RSAXXLAASA-N

InChi Code: InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1

SMILES Code: O=C(OC)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C=CS3)C2.O=S(O)(O)=O

Appearance: White to off-white solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
In vitro activity: DNA fragmentation was found to be increased as a response to 7.5 µM, 40 µM and 75 µM clopidogrel treatment compared to non-treated control groups in AML-12 hepatocytes (p<0.01, p<0.001, p<0.01 respectively) and 3T3-L1 adipocytes (p<0.001, p<0.001 and p<0.001 respectively). DNA damage levels as a response to clopidogrel treatment was found to be higher in 3T3-L1 adipocytes than AML-12 hepatocytes. Reference: Curr Drug Saf. 2021 Jan 6. https://pubmed.ncbi.nlm.nih.gov/33413066/
In vivo activity: The effects of intravenous ADP infusions of 2-8mg/kg/hour were examined in anesthetized Wistar rats that were untreated or chronically pretreated with clopidogrel, 20mg/kg/24hours, a selective P2Y12-R antagonist. ADP induced a gradual, dose-dependent 15% decrease of mean arterial pressure, a sustained increase of renal blood flow and a 25% decrease in renal vascular resistance. Clopidogrel pretreatment attenuated the mean arterial pressure decrease, and did not significantly alter renal blood flow or renal vascular resistance. Reference: Am J Med Sci. 2018 Sep;356(3):287-295. https://pubmed.ncbi.nlm.nih.gov/30293555/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 45.4 108.18
DMF 10.0 23.82
DMF:PBS (pH 7.2) (1:4) 0.2 0.48
Ethanol 43.0 102.41
Water 47.6 113.24

Preparing Stock Solutions

The following data is based on the product molecular weight 419.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Bayar E, Cevik M, Caker S, Cagatay P, Susleyici B. DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel. Curr Drug Saf. 2021 Jan 6. doi: 10.2174/1574886315666210106141936. Epub ahead of print. PMID: 33413066. 2. Roszkowska-Chojecka MM, Walkowska A, Sadowski J, Dobrowolski L. Clopidogrel Partially Counteracts Adenosine-5'-Diphosphate Effects on Blood Pressure and Renal Hemodynamics and Excretion in Rats. Am J Med Sci. 2018 Sep;356(3):287-295. doi: 10.1016/j.amjms.2018.04.013. Epub 2018 Apr 27. PMID: 30293555.
In vitro protocol: 1. Bayar E, Cevik M, Caker S, Cagatay P, Susleyici B. DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel. Curr Drug Saf. 2021 Jan 6. doi: 10.2174/1574886315666210106141936. Epub ahead of print. PMID: 33413066.
In vivo protocol: 1. Roszkowska-Chojecka MM, Walkowska A, Sadowski J, Dobrowolski L. Clopidogrel Partially Counteracts Adenosine-5'-Diphosphate Effects on Blood Pressure and Renal Hemodynamics and Excretion in Rats. Am J Med Sci. 2018 Sep;356(3):287-295. doi: 10.1016/j.amjms.2018.04.013. Epub 2018 Apr 27. PMID: 30293555.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Khodor S, Castro M, McNamara C, Chaulagain CP. Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. Hematol Oncol Stem Cell Ther. 2015 Dec 2. pii: S1658-3876(15)00105-3. doi: 10.1016/j.hemonc.2015.11.003. [Epub ahead of print] PubMed PMID: 26684918.

2: Zhang JR, Wang DQ, Du J, Qu GS, Du JL, Deng SB, Liu YJ, Cai JX, She Q. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore). 2015 Dec;94(50):e2262. doi: 10.1097/MD.0000000000002262. PubMed PMID: 26683949.

3: Yang YG, Zhang M, Jiang N, Song LX, Xu XT, Di XH, Xu L, Xu J, Zhao GT. Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. Genet Mol Res. 2015 Dec 14;14(4):16736-43. doi: 10.4238/2015.December14.1. PubMed PMID: 26681020.

4: Ketterer U, D Ancona G, Siegel I, Ortak J, Ince H, Kische S. Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders. Int J Cardiol. 2015 Nov 24;204:196-197. doi: 10.1016/j.ijcard.2015.11.160. [Epub ahead of print] PubMed PMID: 26670171.

5: Zhai Y, Wang L, Yang F, Feng G, Feng S, Cui T, An L, He X. The mechanism and risk factors of clopidogrel-induced liver injury. Drug Chem Toxicol. 2015 Dec 11:1-8. [Epub ahead of print] PubMed PMID: 26654298.

6: Nishimura AA, Shirts BH, Salama J, Smith JW, Devine B, Tarczy-Hornoch P. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2015 Nov 11. pii: S1386-5056(15)30056-3. doi: 10.1016/j.ijmedinf.2015.11.004. [Epub ahead of print] PubMed PMID: 26642939.

7: Dobesh PP, Varnado S, Doyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. Curr Pharm Des. 2015 Dec 8. [Epub ahead of print] PubMed PMID: 26642781.

8: Braun D, Knipper A, Orban M, Sibbing D, Petzold T, Braun S, Schulz S, Hausleiter J, Kastrati A, Mehilli J, Massberg S. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thromb Res. 2015 Nov 19. pii: S0049-3848(15)30192-4. doi: 10.1016/j.thromres.2015.11.016. [Epub ahead of print] PubMed PMID: 26639204.

9: Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2015 Dec 5. pii: ehv611. [Epub ahead of print] PubMed PMID: 26637834.

10: Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni M, Guzman LA, Bass TA, Ajjan RA, Angiolillo DJ. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost. 2015 Dec 3;115(3). [Epub ahead of print] PubMed PMID: 26633836.